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Particle exposure is known to have negative health effects. In Stockholm the environment
in the subway has been reported to have higher particle exposure levels, measured as PM2.5
and PM10, than roads with intense traffic in the inner city area. We have recently shown
that healthy volunteers exposed to subway environment had statistically significant increase
of fibrinogen and CD4 cells expressing regulatory T-cell marker CD25bright/FOXP3 in blood.
The aim of the present study was to find out whether a more vulnerable population,
asthmatics, would demonstrate similar or other changes in the lungs or in the peripheral
blood.
Sixteen mild asthmatics were exposed to a subway and a control environment for 2 h
while being monitored by measurements of lung function, and inflammatory response in
the lower airways evaluated by bronchoscopy and in peripheral blood. An attempt to stan-
dardize the exposures was done, by letting the volunteers alternate 15 min intervals of
moderate exercise on a bicycle ergometer with 15 min of rest.
We found a statistically significant increased frequency of CD4 cells expressing T-cell
activation marker CD25 in bronchoalveolar lavage fluid, but no significant increase of regu-
latory T-cells in blood as was found in healthy volunteers. Our study shows that airway
inflammatory responses after exposure in subway environment differ between asthmatic
and healthy humans.
ª 2011 Elsevier Ltd. All rights reserved.524 876 82; fax: þ46 8 33 43 33.
nystrom@ki.se (A. Klepczynska-Nystro¨m).
1 Elsevier Ltd. All rights reserved.
Table 1 Basal characteristics for 16 non-smoking
asthmatics.
Volunteer
no
Age Phadiatop
positive
Sex FEV1%
(pred* %)
PD20FEV1
(mg)
1 25 þ M 97 99.0
2 52 e F 116 628.0
3 25 þ M 95 183.0
4 18 þ F 91 <14.2
5 21 þ F 92 585.0
6 23 þ M 109 1889.0
7 18 þ M 127 462.0
8 40 e F 124 581.0
9 31 þ F 113 628.0
10 27 þ F 120 541.0
11 20 þ F 83 256.0
12 21 þ F 95 53.0
13 22 þ M 119 <14.2
14 19 þ F 89 326.0
15 20 þ F 88 54.0
16 33 þ F 103 87.0
Summary Mean 26
(18e52)
years
14
Phadiatop
positive
11 F;
5 M
Mean  SD
104  14
Mean  SD
400  463
Abbreviations: *pred Z predicted; F Z female; M Z male;
FEV1 Z Forced Expiratory Volume in 1 s; PD20FEV1 Z the
cumulative dose of methacholine provoking a 20 percent
decline in FEV1.
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Epidemiological associations between air pollution of
particulate matter and health effects has been widely
discussed over the last years. Particular matter (PM) has
been associated with mortality and hospital admission due
to respiratory and cardiovascular diseases.1e6 The mecha-
nisms are not fully understood, but small particles gener-
ated by combustion are suspected to influence the heart via
inflammation/oxidative stress, accelerated atherosclerotic
processes and changes in the heart rhythm regulation.7,8
Differences in size and chemical composition of particles
need to be considered in association with mortality in the
general population,9 which was shown during exposure to
Saharan dust.10
Allergic respiratory diseases such as asthma have
increased in frequency, putting focus on changes in envi-
ronmental factors in air pollution as genetic predisposition
alone cannot explain the increase. Individuals with asthma
have inflamed airways and are more vulnerable to air
pollutants than a healthy population. Inhalation of particles
may exacerbate the already on-going lung inflammation.11
Asthmatic symptoms and increased need for medication
for asthmatic symptoms are strongest associated with
ultrafine particles and with PM2.5, rather than PM10.
12e15
In Stockholm (Sweden) the environment in the subway
has been reported to have 5e10 higher concentration levels
of particles than roads with intensive traffic in the inner
city area.16 PM2.5 and PM10 mass concentrations levels in
the subway change little from day to day with mean
average of 260 and 470 mg/m3 respectively. The levels of
particles are within levels reported world-wide, with higher
concentrations of particles in subway than in ambient air
such as in Amsterdam,17 Helsinki,18 London,19 New York,20
Rome21 and Seoul.22 The present study was performed in
a subway station with lower particle level, with mean
average of 77 mg/m3 for PM2.5 and 242 mg/m
3 for PM10,
23 but
in the same concentration range as in a road tunnel were
we have previously performed exposure studies.24e26
In the subway particles are rather large, more than 1 mm
in diameter, and mainly originate from railway tracks with
a high content of iron. We have recently shown that healthy
volunteers showed no cellular response in the airways after
exposure to the subway environment. However, in blood we
found a statistically significant increase of fibrinogen and of
regulatory T-cells expressing CD4posCD25bright/FOXP3.23
The aim of this study was to study acute health effects
on individuals with asthma after exposure to a subway
environment, and compare these results with the outcome
of the previous findings in healthy individuals in the same
environment.
Methods
Volunteers
Sixteen non-smoking mild asthmatic volunteers (11 women)
with a mean age of 26 years (range 18e52) participated in
the study. None of the volunteers used the subway on
regular bases for at least two months before the inclusion.
All volunteers underwent a routine physical examination.All had normal chest X-ray. After a baseline registration of
forced expiratory volume during the first second (FEV1),
each volunteer inhaled diluent followed by inhalation of
increasing doses of methacholine, starting at a dose of
14.2 mg, with doubling doses up to an accumulated dose of
7256 mg. The results are expressed as the cumulative dose
causing a 20% decrease in FEV1 (PD20FEV1) compared to
the baseline FEV1. All subjects were hyperresponsive to
methacholine, defined as 20% fall in FEV1.
None of the volunteers were allowed to be medicated
with inhaled corticosteroids, or with other anti-
inflammatory drugs, for the last 3 months before partici-
pation in the study. Short-acting b2-agonist treatment
could be used when needed. An in vitro screening for the
presence of specific IgE antibodies against common inhaled
allergens (Phadiatop, Pharmacia-Upjohn, Uppsala, Swe-
den) showed that 14 of the volunteers (88%) had IgE anti-
bodies, and they also had a positive test for a number of
radioallergosorbents (RAST, Pharmacia-Upjohn). For basal
characteristics of the study population see Table 1.
All participants had given their informed written consent
to participate in the study, which was approved by the
Regional Ethical Review Board, Stockholm, Sweden (2007/
748-31/3).Study design
In order to avoid allergens such as grass and birch, the study
was carried out in Stockholm between mid November and
the beginning of April. The study had a randomized cross-
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a subway environment and an office environment (control)
with at least three weeks interval. For detailed description,
see a previous study performed on healthy subjects with
the same study design.23 Fourteen hours after each expo-
sure bronchoscopy and blood sampling were performed.
Asthmatic volunteers served as their own controls.
During participation in the study the volunteers were told
to perform ordinary daily activities. However, no trans-
portation using the subway system was allowed during the
whole study period. The volunteers were also encouraged
to avoid heavy physical activities during the days of
measurements and to avoid staying in areas with heavy air
pollution. Participants did not have airway infections within
six weeks before exposure occasions.
Location of exposures
The subway exposures were performed during the after-
noon rush hours (4e6 p.m.) at the platform of a subway
station (Odenplan) in the central part of Stockholm. Control
exposures were performed during corresponding hours in an
office environment.
For details of the subway location see the article of
Klepczynska Nystro¨m et al.23
During the exposure sessions the volunteers alternated
15 min intervals of moderate exercise on a bicycle ergom-
eter with 15 min of rest. The ergometer resistance was
adjusted in order to achieve an individual ventilation rate
of 20 L air per minute and m2 of the body surface.
Environmental exposure measurements
Exposure levels were monitored during each exposure
session. Sampling of PM2.5 and PM10 particles (with an upper
50% cut-off aerodynamic diameter of 2.5 respectively
10 mm) in the subway environment, was performed using
Harvard impactors (Air Diagnostics and Engineering Inc.,
Maine, USA) equipped with Teflon filters (Air Diagnostics
and Engineering Inc., Maine, USA) with a pore size of 2 mm
and at a flow rate of approximately 10 L/min. The filters
were weighed after 24 h of conditioning using a Mettler
Toledo MT5 scale (Mettler, Greisensee, Switzerland), but
also analyzed for a range of metals using an inductively
coupled plasma mass spectrometry (ICP-MS). The number
concentration of airborne UF particles was determined
using an upgraded Scanning Mobility Particle Sizer (SMPS)
system, which can detect ultrafine particles with diameter
of 10e100 nm. For comparative reasons we chose to state
particles in the same particle size range as in previous study
(18e100 nm). SMPS consists an Electrostatic Classifier
model 3080 (TSI, Shoreview, MN, USA) in combination with
a Condensation Particle Counter (CPC) model 3010 (TSI).
Nitric oxide (NOx) levels were monitored using a chemilu-
minescent instrument (AC 31M, Environnement, Poissy,
France).
Also portable logging instruments were used: a DataRAM
(MIE pDR1000), that measures the mass of particles
between 0.1 and 10 mm in diameter, and P-Trak, a particle
counter (TSI) estimating the number concentration of
particles with a diameter of 20e1000 nm. Formeasurements in the control environment only portable
instruments were.
Self-reported symptoms
During the exposure sessions self-reported symptoms of
irritation from eyes, nose and lower airways, as well as
experience of disturbing noise and smell, were recorded
before and every 30 min throughout the exposures. The
intensity was graded from 0 to 10, where 0 corresponded to
no symptoms and 10 to severe symptoms, according to
a modified Visual Analogue Scale (VAS).27
Lung function tests
Immediately prior to premedication before bronchoscopies
measurements of lung function were performed with
spirometry (Jaeger Masterscope, Wu¨rzburg, Germany),
which included vital capacity (VC), forced vital capacity
(FVC) and forced expiratory volume during the first second
(FEV1) with a ECCS reference
28 as well as measurements of
exhaled NO levels (Aerocrine, Niox Mino).
Measurements of peak expiratory flow (PEF) were per-
formed with a portable lung health monitor (PIKO-1, Fer-
raris, Louisville, US) before the exposure session and every
hour during the exposure session. In addition, each volun-
teer was instructed to repeat PEF measurements after 2, 4
and 12e13 h after the exposures, as well at the clinic the
following morning approximately 14 h after the exposures.
Peripheral blood
Peripheral blood was sampled in connection to bronchos-
copy. Cell differential counts were performed using an
autoanalyser (Advia 120 Hematology System, Bayer).
Fibrinogen in plasma was analyzed by a kinetic fibrinogen
assay. Plasminogen activator inhibitor-1 (PAI-1) was
analyzed using Enzyme-Linked ImmunoSorbent Assay
(ELISA) (Chromolize PAI-1, Biopool, Trinity Biotech, Bray,
Ireland). Blood was also used for immunostaining and flow
cytometric analysis (see below).
Bronchoscopy, bronchoalveolar lavage and
bronchial wash
Bronchoalveolar lavage (BAL) was performed by inserting
a flexible fiberoptic bronchoscope, (Olympus, Olympus
Optical Co. Ltd., Tokyo, Japan) under local anesthesia, as
described in detail by Eklund and Blaschke29 250 mL sterile
phosphate buffered saline was instilled into the middle lobe
in 5 aliquots of 50 mL each. After each installation the fluid
was gently aspirated and collected and kept on ice.
The BAL fluid (BALF) was filtered through a single layer of
Dacron net (Millipore, Cork, Ireland), centrifuged at 400 g for
10 min at 4 C. The pellet was resolved in RPMI (Roswell Park
Memorial Institute) 1640 medium (SigmaeAldrich, UK). Cells
were counted and total cell viability (mean 94.4%) was
determined by trypan blue exclusion, using a Bu¨rker
chamber. BALF cell pellet was also used for immunostaining
and flow cytometric analysis (see below).
Table 2 Mean  SD values for environmental exposure
measurements in the subway for the study with asthmatics
in comparison with levels for a previously performed study
with healthy volunteers.23 Both studies were performed at
the same subway station and during the same seasons.
Type of exposure Healthy Asthmatics
Ultrafine particles
(number
concentration)
8280  1720/mL 8960  660/mL
PM2.5 (mass
concentration)
77  10 mg/m3 71  13 mg/m3
PM10 (mass
concentration)
242  40 mg/m3 232  51 mg/m3
NO 58  12 mg/m3 43  14 mg/m3
NO2 24  3 mg/m3 20  3 mg/m3
Iron in PM10 58.6  21.0 % 49.3  7.3%
Barium in PM10 1.0  0.4% 0.7  0.1%
Manganese in PM10 0.5  0.2% 0.4  0.1%
Copper in PM10 0.8  0.4% Below detection
limit
Abbreviations: PM2.5 and PM10: particulate mass of particles
with diameter <2.5 and <10 mm, respectively; NO: nitrogen
monoxide; NO2: nitrogen dioxide.
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kines interleukin IL-1B, IL-6, IL-8, IL-10, IL-12p70 and tumor
necrosis factor-a (TNF-a). Cytokine analyses were done by
flow cytometry (FACSCalibur, Becton Dickinson, North Car-
olina, US) using CBA (Cytometric Bead Array) technique
(Becton Dickinson, North Carolina, US).
Bronchial wash was done in a segmental bronchus in an
upper lobe by installing 2  10 mL sterile phosphate buff-
ered saline. Each installation was followed by aspiration of
fluid.
Immunostaining and flow cytometric analysis
Lymphocyte subsets were determined in BALF and eryth-
rocyte lysed human peripheral blood using the TBNK 6 color
Multitest. TBNK consists of a combination of fluorochrome
conjugated monoclonal antibodies for T-cells, B-cells and
NK-cells. We also used a set of monoclonal antibodies
specific for markers of T-cell activity and of T-cell regula-
tory functions. The monoclonal antibodies that were used
for phenotypic characterization of lymphocyte subsets was
as follows: CD3 (T-cell marker), CD4 (T-helper cells/regu-
latory T-cells), CD8 (T-cytotoxic/suppressor), CD25 (Anti-IL-
2R-activation), CD45 (white blood cells), CD69 (early acti-
vation), CD56posCD16pos (NK-cells or NK-T-cells), CD19 (B-
cells), HLA-DR (MHC II activation), Forkhead box P3 (FOXP3)
(T-regulatory cell). All monoclonal antibodies were from BD
Biosciences, San Jose, CA, USA, with the exception of
FOXP3 which was obtained from eBiosciences, San Jose,
CA, USA.
For each analysis, 1  106 BALF cells were incubated
with antibodies for 30 min in the dark and kept on ice at
4 C, while blood was kept at room temperature. Blood
samples were lysed with lysing solution and washed twice
with cell wash (BD Biosciences, San Jose, CA, USA). All
samples were analyzed by a flow cytometer using an 8 color
FACSCanto II (BD Franklin Lakes, NJ USA). Approximately
2.5  105 cells were collected from each sample.
Lymphocytes were gated by forward and side scatters. For
the TBNK Multitest a gate was set for CD45 (white blood
cells). For the T-cell activation and T-regulatory panels
a gate was set for CD3 cells (T-cells). Isotype matched
negative control antibodies always stained less than 1%.
Statistical analysis
Statistical analysis was carried out with SPSS version 17.0
on a Windows based PC platform (SPSS Inc, Chicago, Illinois,
USA). Individual changes in different parameters for subway
and control exposure were analyzed using Wilcoxon’s non-
parametric rank sum tests. A paired t-test was performed
for lung function data and exposure measurements. Values
of p < 0.05 were regarded as significant.
Results
Environmental exposure measurements
The exposure levels, for both control and subway environ-
ment, were similar to the previous study. Subway exposureswere performed at totally eleven occasions. A comparison
of exposure levels for PM2.5, PM10, UF particles, NO and NO2
for both studies are presented in Table 2, as well as the
content of metals in the PM10 fraction (mean level  SD).
All but three metals (iron, barium and manganese) were
below the detection limits (ICP-MS).
In the control exposures the particle concentration of
0.1e10 mm (using DataRAM) was 18  4 mg/m3 (mean
level  SD), while the number concentration of particles
with a diameter of 20e1000 nm (using P-Trak) was
910  420 particles/mL. The levels with the same equip-
ment in the subway environment were 150  30 mg/m3 and
9330  1290 mg/m3, respectively.Symptoms
In comparison with the control exposures, self-reported
symptoms of irritation from the eyes, nose and experience
of disturbing smell were significantly higher during the
exposure to the subway environment, see Table 4. No
significant increase of irritations in the lower airways or
experience of disturbing noise was reported.Lung function tests
Fourteen hours after each exposure no significant changes
between subway and control exposures were observed
with regard to VC, FVC, FEV1 or exhaled NO. None
significant changes were seen in mean PEF performed
2e14 after the exposures or for PEF quotient (after
exposure/before exposure). For details see Appendix
(additional material).
Table 3 Overview of findings for T-cells expressing markers analyzed for healthy,23 and asthmatic volunteers respectively.
Analyses were done in erythrocyte-lysed human peripheral blood and bronchoalveolar lavage (BAL) fluid after volunteers being
the exposed to control and subway environment. The data is presented as medians (interquartile ranges).
CD4pos cells markers Healthy Asthmatics
Control exposure Subway exposure p-value Control exposure Subway exposure p-value
Regulatory T-cell marker (%)
FOXP3 in blood 2.1 (1.5e5.4) 4.3 (2.5e5.9) 0.03 1.8 (1.4e2.6) 2.0 (1.1.-3.1) 0.4
FOXP3 in BAL fluid 8.1 (5.2e9.4) 8.8 (7.5e10.9) 0.1 6.8 (5.7e7.8) 7.3 (5.9e10.7) 0.4
CD25bright/FOXP3 in blood 2.1 (0.8e2.7) 2.8 (1.7e4.5) 0.03 1.0 (0.6e1.2) 0.8 (0.5e1.4) 0.7
CD25bright/FOXP3 in BAL fluid 4.9 (3.7e6.8) 5.4 (3.9e6.0) 0.8 4.9 (3.5e6.1) 4.5 (3.8e6.7) 0.2
T-cell activation (%)
CD25 in BAL fluid 7.8 (6.6e9.2) 8.8 (7.2e10.9) 0.5 7.4 (6.0e9.6) 9.5 (6.4e12.2) 0.03
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The total number of cells, cell concentrations and distri-
bution of different cell populations in peripheral blood did
not differ between control and subway exposures. Neither
fibrinogen nor PAI-1 levels in the peripheral blood were
affected. Levels of PAI-1 were often below the detection
limit of <5 kilounits/L (10 volunteers after the subway
exposure respectively 9 after the control). In order to
perform statistical analysis, these cases were assigned
a value of 3. For details see Appendix (additional material).
Bronchoalveolar lavage fluid and bronchial wash
No significant changes were seen in BALF or bronchial wash
fluid between subway and control exposures with regard to
recovery, cell viability, the total number of cells, cell
concentration and distribution of different cell pop-
ulations. Neither any significant change was seen in cyto-
kines expression in the BALF. For details see Appendix
(additional material).Table 4 (additional material). Changes in different parameters
exposed to control and subway environments.
Parameter
Lymphocyte subsets
in blood (CD3, CD4, CD8, CD25,
CD19, CD45, CD56posCD16pos,
CD69, HLA-DR, FOXP3)
Lymphocyte subsets in BAL fluid
(as above)
Self-reported symptoms during exposure
(irritation from eyes, nose, lower
airways; disturbing noise and smell)
Fibrinogen in blood
Abbreviations: ns Z non-significant; significance Z values of p <
exposure in comparison to control exposure; BALZ bronchoalveolar la
Appendix.Immunostaining and flow cytometric analysis
In BALF the percentage of CD4pos T-cell population express-
ing T-cell activation marker interleukin-2 (IL-2) receptor
alpha chain (CD25) increased significantly after exposure in
the subway (p< 0.03). In blood, no corresponding significant
increase was seen. See Table 3 and Fig. 1.
No other significant change in TBNK-cells or lymphocyte
subsets was seen after exposure in the subway. For
comparative data with a previous study with healthy on
regulatory T-cells and CD4 cells expressing the T-cell acti-
vation marker CD25, see Tables 3 and 4. No significant
changes in the ratio between the T-helper/regulatory
cells(CD4)/T-cytotoxic-suppressor cells (CD8) in BALF was
found. It was 1.5 (control) versus 1.7 (subway). The ratio in
blood was 2.5 (control) versus 2.3 (subway).
Discussion
Inhaled particles in air pollution may exacerbate the already
on-going lung inflammation in asthmatics.11 The meanin healthy and asthmatic volunteers, respectively, after being
Healthy16 Asthmatics
CD4pos/CD69pos
ns
CD4pos/HLA-DRpos
CD8pos/CD69pos
CD4pos/FOXP3
CD4posD25bright/
FOXP3
ns CD4pos/CD25
lower airways
disturbing
smell
eyes
nose
disturbing
smell
ns
0.05 were regarded as significant with an increase after subway
vage; BWZ bronchial wash. For descriptive data, see Table 3 and
Figure 1 Percentage of CD4 cells expressing the T-cell acti-
vation marker CD25 (CD4pos/CD25pos) in bronchoalveolar lavage
fluid (BALF) and peripheral blood after control and subway
exposure. Data is presented as medians (interquartile ranges).
(a) In BALF, the relative number increased from 7.4 (6.0e9.6)
after control exposure to 9.5 (6.4e12.2) after subway exposure
(pZ 0.03). (b) In blood the relative number increased from 1.6
(1.3e2.6) after control exposure to 2.0 (1.1e3.1) after subway
exposure.
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levels reported world-wide in scientific litera-
ture.17,18,20,21,30 We have found that mild asthmatics
exposed to subwayenvironment for 2 h,with particlesmainly
containing iron, showed statistically significant increase in
percentage of lung recruited CD4 cells expressing the T-cell
activation marker CD25 (CD4pos/CD25pos) in comparison to
a control exposure. CD25pos is a general activation marker
present on activatedT-cells in inflammatory reactions, but in
situations with no ongoing immune response it is also an
appropriate marker for natural regulatory T-cell with
a frequency of 5e10% in bothmice and human blood.31 In our
study the CD4pos/CD25pos changes were seen in BAL, but not
in blood, which suggest a local effect on lungs.
There is to our knowledge no other study that has inves-
tigated acute health effects in asthmatics caused by expo-
sure in the subway environment. Acute health effects in
asthmatics to environmental pollutants may differ depend-
ing on the composition and concentration of pollutants, as
well as on the severity of asthma. In our study we have
chosen a group of “mild asthmatics”, with no regular need of
medication for asthma. Another in vivo study on asthmatics
was undertaken where they were exposed for 2 h in a busy
road in London.32 Car exhausts causes exposure to much
higher number concentration of ultrafine particles than
subway environment does. The road traffic exposure hada negative effect on the lung function of the asthmatics
measured as FEV1 and FVC in comparison to exposure in
a park. The effects were greater in moderate asthmatics
compared to mild asthmatics. Associations were strongest
with ultrafine particles and with elemental carbon. The
association with ultrafine particles, rather than with PM2.5
and PM10, and asthmatic symptoms and increased need of
medication, has been shown in other studies.12e15
Wehave previously performed an identical in vivo study in
the subway environment with healthy volunteers. The
exposure levels of PM2.5 and PM10, number concentration of
ultrafine andNOx,were in the sameorder ofmagnitude in the
two studies. No significant increase of CD4 cells expressing T-
cell activation marker CD25 was found in healthy.23 Healthy
demonstrated significant increasedexpression ofmarkers for
regulatory T-cells (CD4posCD25bright/FOXP3), as well as
elevated levels of fibrinogen in peripheral blood, after being
exposed to the subwayenvironment. Even though asthmatics
are known to be more sensitive to air pollution than
healthy,33 this was not seen in asthmatics.
Studies on T-regs in asthmatics is quite novel.34 Gener-
ally T-regulatory cells are important in balancing or sup-
pressing immune responses. At present there limited
knowledge regarding the role of T-regs in asthma, but
evidence suggests that asthma is characterized by a rela-
tive deficiency in T-regs.31 Such tendency was also seen in
our study. In an in vivo study evaluation was done on
circulating T-reg cells in 14 control subjects and 29 patients
with asthma.35 In both groups numbers of peripheral blood
CD4posCD25high and CD4posCD25high/FOXP3 T-cells were
similar, but asthmatic patients had decreased FOXP3
protein expression within their CD4posCD25high T-regs.
Interestingly treatment of asthmatics with glucocorticos-
teroids had a tendency to increase FOXP3 expression within
CD4posCD25high T-cells, when compared to steroid-naive
asthmatic patients. In our study none of the asthmatic
volunteers was treated with glucocorticosteroids.
In our study asthmatics reported significant increased
irritation in the eyes and the nose during the exposure to the
subway environment, as well as increased experience of
disturbing smell. Similar to asthmatics, a self-reported
experience of a disturbing smell was registered in healthy
volunteers, but they had no significant changes in irritations
in the eyes or in the nose. Instead healthy reported increased
signs of irritation in the lower airways. For summary of
comparative data, see Table 4 (additional material).
Overall the acute health effects after exposure to subway
environment are few. The main result from our study shows
that a 2 h long exposure of asthmatic individuals leads to
a different T-cell response than for healthy volunteers in our
previous study. There is a local activation of T-cells in asth-
matics in BAL fluid, while healthy demonstrate a systemic
increase of regulatory T-cells in blood that suppresses the
inflammatory response. It is still too early to conclude if this
difference has any influence on real health risk, but it would
be of interest to expand the follow-up time frame with
repeated measurements to monitor possible earlier or later
effects on the inflammatory responses. BAL is not a suitable
method for repetitive measurements, while repeated blood
sampling could be used. In healthy volunteers, inflammatory
effects were seen in blood, which makes them as interesting
and feasible group to test.
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Outcome parameter Healthy
Control
exposure
Healthy
Subway
exposure
Lung function
VC (predicted %) 109  14 111  13
FVC (predicted %) 112  13 112  14
FEV1 (predicted %) 105  12 105  14
Exhaled NO (ppb) 18  8 17  9
PEF, 2e14 h after
exposure (L/min)
537  138 522  113
PEF quotient (after
exposure/before
exposure)
1.0 0.96
Blood cell concentration (109/L)
Leucocytes 5.7 (5.1e6.7) 5.6 (5.2e
Neutrophils 2.8 (2.6e4.0) 2.9 (2.5e
Eosinophils 0.1 (0.1e0.2) 0.1 (0.1e
Basophils 0.1 (0.1e0.1) 0.1 (0.1e
Lymphocytes 2.4 (2.0e2.6) 2.4 (1.9e
Monocytes 0.4 (0.3e0.4) 0.4 (0.3e
Blood differential (%)
Neutrophils 50.8 (46.5e54.8) 51.7 (45.8
Eosinophils 2.0 (1.8e3.0) 2.0 (1.8e
Basophils 1.8 (1.5e2.0) 1.8 (1.6e
Lymphocytes 40.2 (35.1e43.9) 40.5 (35.9
Monocytes 5.9 (5.3e7.0) 6.1 (5.0e
Bronchoalveolar lavage (BAL) findings
Recovery (%) 74.0 (71.2e78.2) 70.7 (64.5
Viability (%) 95.3 (91.3e98.1) 95.5 (94.3
Total number
of cells (*106)
14.3 (12.3e17.8) 12.7 (10.1
Total cell
concentration (*106/L)
79.5 (67.8e98.9) 75.1 (59.2
Number of mast cellsa 1.5 (0.0e5.0) 1.5 (1.0e
Cell concentrations in BAL fluid (106L)
Macrophages 66.8 (56.7e84.9) 60.4 (50.1
Lymphocytes 8.8 (5.6e17.2) 8.2 (6.0e
Neutrophils 1.4 (0.9e1.9) 1.7 (1.1e
Eosinophils 0.1 (0.0e0.4) 0.1 (0.0eH. Blomqvist, M. Dahl, G. De Forest, B. Dahlberg (all Dept of
Medicine, Karolinska Institutet), S. Gustavsson (Institute of
Environmental Medicine, Karolinska Institutet) and L. Bro-
man (Dept of Clinical Sciences, Karolinska Institutet), I.
Ro¨din (University Hospital of North Norway, Tromsø in Nor-
way) for their excellent technical assistance in this project.
This study was sponsored by the Swedish Rail Administration
(Banverket) and supported by the Mats Kleberg Foundation
and Karolinska Institutet (Stockholm, Sweden).arameters for healthy23 respectively asthmatic volunteers
r lung function are presented as mean  SD, while data for
for bronchoalveolar lavage and bronchial wash findings are
Asthmatics
Control
exposure
Asthmatics
Subway
exposure
103  15 101  11
108  13 107  13
102  16 103  17
43  42 40  36
469  119 460  116
0.98 0.96
6.5) 5.6 (5.2e7.1) 5.5 (5.1e6.2)
3.6) 2.6 (2.0e3.4) 2.5 (2.1e3.3)
0.2) 0.4 (0.1e0.5) 0.2 (0.1e0.4)
0.1) 0.1 (0.1e0.1) 0.1 (0.1e0.1)
2.7) 2.5 (1.9e2.7) 2.2 (1.9e2.7)
0.4) 0.6 (0.5e0.7) 0.5 (0.5e0.6)
e54.9) 44.3 (39.1e53.1) 44.7 (38.5e52.8)
3.4) 6.5 (2.3e8.6) 3.9 (2.6e6.8)
1.9) 1.8 (1.4e1.9) 1.8 (1.6e2.0)
e45.2) 39.6 (32.9e44.4) 39.9 (35.1e43.1)
7.1) 9.5 (8.6e12.2) 9.4 (7.3e12.7)
e75.4) 70.5 (55.0e78.8) 69.0 (61.8e75.2)
e97.7) 92.0 (90.0e94.8) 92.9 (90.3e95.0)
e17.0) 13.7 (9.2e19.0) 12.7 (10.4e23.1)
e96.2) 81.2 (60.0e125.4) 98.6 (64.1e149.7)
4.0) 4.0 (1.0e8.8) 2.5 (1.0e4.8)
e86.1) 65.0 (52.6e103.5) 80.2 (54.6e137.4)
13.5) 8.9 (5.1e18.0) 11.3 (8.8e15.2)
2.4) 1.4 (0.8e2.4) 1.6 (0.7e3.0)
0.5) 0.5 (0.3e1.1) 0.5 (0.1e2.5)
(continued on next page)
(continued )
Outcome parameter Healthy
Control
exposure
Healthy
Subway
exposure
Asthmatics
Control
exposure
Asthmatics
Subway
exposure
Basophils 0.0 (0.0e0.0) 0.0 (0.0e0.0) 0.0 (0.0e0.0) 0.0 (0.0e0.1)
Cell differential in BAL fluid (%)
Macrophages 85.9 (80.4e89.4) 85.3 (81.9e88.3) 85.7 (80.0e89.7) 83.4 (79.2e90.1)
Lymphocytes 11.3 (8.3e17.9) 11.4 (8.2e15.9) 11.0 (7.6e14.8) 11.9 (7.7e15.5)
Neutrophils 1.9 (1.2e2.2) 2.2 (1.4e3.0) 1.5 (0.8e2.5) 1.8 (0.9e2.9)
Eosinophils 0.2 (0.0e0.4) 0.2 (0.0e0.6) 0.6 (0.2e1.6) 0.6 (0.3e2.4)
Basophils 0.0 (0.0e0.0) 0.0 (0.0e0.0) 0.0 (0.0e0.0) 0.0 (0.0e1.2)
Bronchial wash (BW) findings
Recovery (%) 40.0 (37.0e50.0) 40.0 (35.0e50.0) 60.0 (40.0e60.0) 55.0 (50.0e60.0)
Viability (%) 82.0 (67.0e94.0) 75.0 (58.0e86.0) 94.5 (84.3e99.5) 90.0 (86.8e97.3)
Total number
of cells (*106)
0.4 (0.2e0.8) 0.7 (0.3e1.0) 0.4 (0.1e0.7) 0.4 (0.2e0.7)
Total cell
concentration (*106/L)
52.5 (30.0e99.1) 85.0 (36.0e133.0) 31.5 (14.9e61.6) 33.8 (21.5e55.4)
Number of mast cellsa 2.0 (0.0e4.5) 2.0 (0.0e3.0) 4.0 (1.0e15.0) 3.0 (2.0e16.5)
Cell concentrations in BW fluid (106/L)
Macrophages 51.9 (51.7e52.2) 57.8 (57.8e57.8) 26.3 (14.1e36.0) 23.4 (12.9e40.8)
Lymphocytes 2.2 (2.1e2.3) 6.9 (6.9e6.9) 2.7 (0.9e4.3) 2.6 (1.0e4.7)
Neutrophils 14.7 (3.3e26.0) 5.2 (5.2e5.2) 3.8 (1.5e5.2) 2.7 (1.2e4.8)
Eosinophils 0.1 (0.1e1.2) 0.1 (0.1e0.1) 0.2 (0.0e0.4) 0.2 (0.1e0.8)
Basophils 0.0 (0.0e0.0) 0.0 (0.0e0.0) 0.0 (0.0e0.0) 0.0 (0.0e0.0)
Cell differential in BW fluid (%)
Macrophages 64.6 (56.8e73.0) 55.8 (41.3e76.8) 80.9 (68.2e83.6) 76.5 (68.6e89.0)
Lymphocytes 5.6 (3.5e8.2) 5.7 (3.6e10.0) 8.3 (3.4e11.6) 8.0 (5.6e11.5)
Neutrophils 28.0 (18.2e34.5) 38.3 (11.4e54.0) 13.0 (6.2e19.2) 12.0 (2.0e18.0)
Eosinophils 0.2 (0.0e0.5) 0.3 (0.0e0.7) 0.8 (0.0e1.0) 0.7 (0.3e3.1)
Basophils 0.0 (0.0e0.0) 0.0 (0.0e0.0) 0.0 (0.0e0.0) 0.0 (0.0e0.0)
Cytokine concentrations in BAL fluid (pg/L)
IL-1B 79.8 (57.8e165.9) 64.9 (53.1e139.8) 284.2 (154.4e439.0) 166.3 (92.1e296.4)
IL-6 394.9 (263.2e963.0) 391.9 (272.0e686.4) 711.6 (529.4e1287.4) 534.5 (398.6e1152.9)
IL-8 8569.5
(4646.8e19802.3)
4901.0
(3696.0e14260.0)
12 718.0
(6513.0e16723.0)
12 359.0
(5535.0e18459.0)
IL-10 15.2 (5.5e21.2) 9.6 (6.3e17.3) 26.4 (21.3e30.4) 20.1 (15.6e30.0)
IL-12p70 14.8 (10.6e24.0) 13.7 (8.0e22.1) 17.4 (0.0e28.5) 0.0 (0.0e20.0)
TNF-a 8.9 (1.0e58.6) 8.2 (0.0e49.0) 14.2 (8.4e46.3) 17.0 (0.0e54.3)
PAI-1 in blood (kilounits/L)
PAI-1 3 (3e11) 3 (3e11) 3 (3e9) 3 (3e10)
Fibrinogen (g/L)
Fibrinogen in blood 2.2 (2.00e2.38) 2.3 (2.21e2.58) 2.6 (2.2e2.9) 2.4 (2.2e2.9)
a Enlarged 16 times/10 visual field.
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